

2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Xeljanz - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.**

Q1. Is the requested drug being prescribed by or in consultation with a rheumatologist, dermatologist, or gastroenterologist?
 Yes No

Q2. Does the patient have the diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) or active polyarticular course juvenile idiopathic arthritis (PJIA)?
 Yes No

Q3. Is there documentation of an inadequate response, intolerance, or contraindication to at least one TNF blocker for RA, PsA and AS, or to at least one first-line therapy (including full-dose NSAIDs) for PJIA?
 Yes No

Q4. Does the patient have the diagnosis of ulcerative colitis (UC)?
 Yes No

Q5. Is there documentation of an inadequate response, intolerance, or contraindication to at least one treatments (such as one of the following: tumor necrosis factor antagonist, oral or intravenous corticosteroid, azathioprine or 6-MP)?
 Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Xeljanz - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
----------------------	-------------------------

<p>Q6. Is the patient 18 years of age or older for RA, PsA, AS or UC, or 2 years of age or older for PJIA?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q7. Has the patient been evaluated for current infections including active or latent tuberculosis (TB) infection with a tuberculin skin test prior to the initiation of therapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q8. Was the tuberculin skin test negative?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Is there a treatment plan for the active or latent infection?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Will the requested drug be used concomitantly with other biologic disease modifying anti-rheumatic drugs (DMARDs) or potent immunosuppressants (such as azathioprine or cyclosporine)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Requested Duration:</p> <p><input type="checkbox"/> 12 months <input type="checkbox"/> Other</p>
<p>Q12. Additional Information:</p>

Prescriber Signature

Date

2024 Medicare Prior Authorization Request